Hansen Medical's total free cash flow for the
months ended in Mar. 2016 was
$-7.89 Mil.
Its total free cash flow for the trailing twelve months (TTM) ended in Mar. 2016 was $-37.97 Mil.
Hansen Medical's Free Cash Flow per Share for the
months ended in Mar. 2016 was $-0.42.
Its free cash flow per share for the trailing twelve months (TTM) ended in Mar. 2016 was $-2.15.
The historical data trend for Hansen Medical's Free Cash Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.
Hansen Medical's Free Cash Flow for the fiscal year that ended in Dec. 2015 is calculated as
Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.97 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansen Medical (NAS:HNSN) Free Cash Flow Explanation
Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.
In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.
This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:
If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.
The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).
For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.
Hansen Medical Free Cash Flow Related Terms
Thank you for viewing the detailed overview of Hansen Medical's Free Cash Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Hansen Medical (Hansen Medical) Business Description
Hansen Medical Inc, formerly known as AutoCath Inc, was incorporated in Delaware in 2002. The Company completed its initial public offering on February 28, 2014. The Company develops, manufactures and sells medical robotics designed for accurate positioning, manipulation and stable control of catheters and catheter-based technologies. Its products include Sensei Robotic Catheter System, Magellan Robotic System, Artisan catheter, Lynx catheter, Magellan Robotic Catheter, and CoHesion 3D Visualization Module. Sensei Robotic Catheter System, or Sensei system, is designed to allow physicians to navigate flexible catheters with solid stability and control in interventional procedures within the atrial heart chambers. This system enables physicians to direct the movements of a robotic catheter like the Company's Artisan Control Catheter and Artisan Extend Control Catheter, or Artisan catheters, and Lynx Robotic Ablation Catheter, or Lynx catheter, to an anatomical location. The Sensei system is comprised of two modules: a physician control console and a patient-side module that can be connected to procedure tables. The control console can be located inside the Electro-Physiology Laboratory, or EP lab, and close to the patient or outside the EP lab in a separate location shielded from radiation. The Company's Magellan Robotic System is a peripheral vascular interventional platform that, used in combination with the Magellan Robotic Catheters, has the potential to provide endovascular specialists with vessel navigation, catheter stability during the manual delivery and placement of therapeutic devices, reduced procedural radiation exposure and fatigue, and precise robotic control of distal catheter tips. Magellan Robotic System is comprised of two modules: a physician control console and a patient-side robotic arm that can be connected to procedure tables. The Artisan catheter is a disposable catheter and guide catheter assembly that consists of a telescoping set of control catheters that are integrated to provide the desired motion of the tip of a diagnostic or therapeutic catheter that is inserted through the center lumen of the Artisan catheter. This is designed to accurately control the movement of a third party catheter chosen by the physician. CoHesion 3D Visualization Module, or CoHesion Module, is a software interface between Sensei system and the St. Jude Medical EnSite System for EP procedures. It is designed to provide physicians with 3D visualization to augment their ability to move a catheter throughout the atria, as well as increase control over placement of the catheter in specific locations. The Company markets, sells and supports its products in the United States through a direct sales force of regional sales employees, supported by clinical account managers who provide training, clinical support and other services to customers. Outside the United States, in the European Union, it uses a combination of a direct sales for
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HNSN has been successfully added to your 